Celladon to Host Investor and Analyst Day and Webcast on May 6th in New York City
April 29, 2014 07:00 ET
|
Celladon Corporation
SAN DIEGO, April 29, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in...
Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR(R), Novel, First-in-Class Therapy in Development to Treat Heart Failure
April 10, 2014 08:30 ET
|
Celladon Corporation
SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases...
Celladon Added to the Russell 2000(R) and Russell 3000(R) Indexes
April 01, 2014 07:00 ET
|
Celladon Corporation
SAN DIEGO, April 1, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the...
Celladon Reports Fourth Quarter and Year-End 2013 Financial Results and Recent Highlights
March 31, 2014 16:05 ET
|
Celladon Corporation
SAN DIEGO, March 31, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in...
Celladon to Report Fourth Quarter and Year-End 2013 Results on Monday, March 31, 2014
March 21, 2014 07:00 ET
|
Celladon Corporation
Investor Call Scheduled for 4:30pm Eastern on Monday, March 31, 2014
SAN DIEGO, March 21, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company...
Celladon to Present at BioCentury's Future Leaders in the Biotech Industry Conference
March 20, 2014 16:15 ET
|
Celladon Corporation
SAN DIEGO, March 20, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in...
Celladon to Present at Barclays Global Healthcare Conference 2014
March 05, 2014 08:01 ET
|
Celladon Corporation
SAN DIEGO, March 5, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the...
Celladon Completes Enrollment of CUPID 2 Trial for Advanced Heart Failure
March 04, 2014 07:30 ET
|
Celladon Corporation
SAN DIEGO, March 4, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the...
Celladon Corporation Announces Appointments of Dr. Peter Honig and Dr. Patrick Yang to Its Board of Directors
March 03, 2014 08:00 ET
|
Celladon Corporation
SAN DIEGO, March 3, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the...
Celladon Announces Exercise in Full and Closing of Underwriters' Option to Purchase Additional Shares
February 27, 2014 16:25 ET
|
Celladon Corporation
SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the...